Literature DB >> 18284629

PET/CT in the management of haematological malignancies.

Martin Hutchings1, Lena Specht.   

Abstract

Positron emission tomography (PET)/computerised tomography (CT) has proved useful in a number of haematological malignancies, particularly in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphomas (NHL). It is recommended in the staging of HL and aggressive NHL, it has been shown to be prognostically important early during treatment, and it has been incorporated in the response criteria. However, treatment modification based on early scans is still experimental, and routine use in follow up cannot be recommended. The use of PET/CT in other lymphoma types and other haematological malignancies is still under evaluation.

Entities:  

Mesh:

Year:  2008        PMID: 18284629     DOI: 10.1111/j.1600-0609.2008.01051.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Predicting the clinical course of Hodgkin lymphoma.

Authors:  Alberto Fabbri; Alessandro Gozzetti; Francesco Forconi; Francesco Lauria
Journal:  Nat Rev Clin Oncol       Date:  2010-08       Impact factor: 66.675

2.  ¹⁸F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia.

Authors:  Friedrich Stölzel; Christoph Röllig; Jörgen Radke; Brigitte Mohr; Uwe Platzbecker; Martin Bornhäuser; Tobias Paulus; Gerhard Ehninger; Klaus Zöphel; Markus Schaich
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

3.  FDG PET/CT predictive role in follicular lymphoma.

Authors:  Egesta Lopci; Lucia Zanoni; Arturo Chiti; Cristina Fonti; Ivan Santi; Pier Luigi Zinzani; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-22       Impact factor: 9.236

Review 4.  Targeting the Warburg effect in hematological malignancies: from PET to therapy.

Authors:  Mala Shanmugam; Samuel K McBrayer; Steven T Rosen
Journal:  Curr Opin Oncol       Date:  2009-11       Impact factor: 3.645

5.  18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma.

Authors:  M J Shelly; S McDermott; O J O'Connor; M A Blake
Journal:  ISRN Hematol       Date:  2012-03-11

6.  Utility of fluorodeoxyglucose positron emission tomography/computed tomography in patients with fever of unknown origin diagnosed as lymphoma.

Authors:  Zi-Ke Sheng; Jin Ye; Jun-Jie Li; Kui Zhao; Ji-Fang Sheng
Journal:  Med Princ Pract       Date:  2014-07-17       Impact factor: 1.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.